<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959686</url>
  </required_header>
  <id_info>
    <org_study_id>&quot;BENTLY&quot;</org_study_id>
    <nct_id>NCT00959686</nct_id>
  </id_info>
  <brief_title>Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma</brief_title>
  <acronym>BENTLY</acronym>
  <official_title>Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma. A Phase II Multicenter Study &quot;BENTLY&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mundipharma Pte Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II clinical study to determine the efficacy of single agent Bendamustine for T cell
      lymphoma &quot;BENTLY&quot;.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to define the activity of Bendamustine for the
      treatment of T cells lymphomas. The activity of Bendamustine is determined by the response
      rate (RR) to the treatment within 22 days after intravenous infusion which enables to get a
      confidence interval of 95 % for the probability of an overall response rate (ORR).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the overall response rate (ORR) (CR+CRu+PR)</measure>
    <time_frame>36 months follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the tolerance and Safety of bendamustine in this subset of patients</measure>
    <time_frame>36 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the progression free survival (PFS), time to treatment failure (TTF), time to progression (TTP), overall survival (OS) and the duration of response.</measure>
    <time_frame>36 months follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles</description>
    <arm_group_label>Bendamustine</arm_group_label>
    <other_name>Ribomustin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged more than 18 years.

          -  Refractory or relapsed peripheral T-cell NHL (PTCL)

          -  Cutaneous T cell lymphoma (CTCL) in relapse or refractory to topical therapy

          -  ECOG score less than 2

          -  No major organ dysfunction unrelated to lymphoma.

        Exclusion Criteria:

          -  Pregnant or breast feeding women

          -  ECOG score &gt; 2

          -  Estimate survival time &lt; 3 months

          -  Active infection or severe organ dysfunction or psychiatric condition that unable
             patients to receive chemotherapy

          -  Creatinine clearance &lt; 10 ml/min or severe hepatic dysfunction not related to
             lymphoma.

          -  Previous chemotherapy/immunotherapy within 3 weeks before study entry

          -  Known seropositive for or active viral infection HIV, EBV, HCV

          -  CNS lymphoma

          -  T-cell Leukemia lymphoma associated with HTLV1

          -  Sezary syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gandhi DAMAJ, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rémy GRESSIN, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>THierry LAMY, PD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier TOURNILHAC, PD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr Gandhi DAMAJ</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2009</study_first_submitted>
  <study_first_submitted_qc>August 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2009</study_first_posted>
  <last_update_submitted>February 11, 2013</last_update_submitted>
  <last_update_submitted_qc>February 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bendamustine refractory or relapsed T-cell lymphoma.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

